| 1.95 -0.01 (-0.51%) | 06-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.62 | 1-year : | 2.95 |
| Resists | First : | 2.25 | Second : | 2.52 |
| Pivot price | 1.96  |
|||
| Supports | First : | 1.79 | Second : | 1.49 |
| MAs | MA(5) : | 1.91  |
MA(20) : | 2.01 |
| MA(100) : | 1.71 |
MA(250) : | 1.42 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 30.1 |
D(3) : | 25.1 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 2.52 | Low : | 0.69 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LXRX ] has closed above bottom band by 46.0%. Bollinger Bands are 11.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.03 - 2.04 | 2.04 - 2.04 |
| Low: | 1.9 - 1.91 | 1.91 - 1.92 |
| Close: | 1.93 - 1.95 | 1.95 - 1.96 |
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Thu, 11 Jun 2026
Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now? - Yahoo Finance
Thu, 11 Jun 2026
LXRX News | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Thu, 04 Jun 2026
Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into 213,771-share stake - Stock Titan
Thu, 04 Jun 2026
Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into common stock holdings - Stock Titan
Thu, 04 Jun 2026
Diane E. Sullivan converts 89,312 RSUs at Lexicon Pharmaceuticals (LXRX) - Stock Titan
Thu, 04 Jun 2026
How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst Updates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 444 (M) |
| Held by Insiders | 2.6253e+008 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 23,860 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.367e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -37.5 % |
| Operating Margin | -4.8 % |
| Return on Assets (ttm) | -5.4 % |
| Return on Equity (ttm) | -16.1 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 534.67 |
| Sales Per Share | 6.50841e+007 |
| EBITDA (p.s.) | 6.12617e+007 |
| Qtrly Earnings Growth | -0.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -13.8 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 4.34 |
| Dividend | 0 |
| Forward Dividend | 2.621e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|